242 related articles for article (PubMed ID: 15701882)
1. Therapeutic observations in MCF-7 aromatase xenografts.
Brodie A; Jelovac D; Macedo L; Sabnis G; Tilghman S; Goloubeva O
Clin Cancer Res; 2005 Jan; 11(2 Pt 2):884s-8s. PubMed ID: 15701882
[TBL] [Abstract][Full Text] [Related]
2. Model systems: mechanisms involved in the loss of sensitivity to letrozole.
Brodie A; Jelovac D; Sabnis G; Long B; Macedo L; Goloubeva O
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):41-8. PubMed ID: 15967659
[TBL] [Abstract][Full Text] [Related]
3. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
4. Aromatase and breast cancer.
Brodie A; Sabnis G; Jelovac D
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
[TBL] [Abstract][Full Text] [Related]
5. Xenograft models for aromatase inhibitor studies.
Brodie A; Sabnis G; Macedo L
J Steroid Biochem Mol Biol; 2007; 106(1-5):119-24. PubMed ID: 17611101
[TBL] [Abstract][Full Text] [Related]
6. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
Lu Q; Liu Y; Long BJ; Grigoryev D; Gimbel M; Brodie A
Breast Cancer Res Treat; 1999 Sep; 57(2):183-92. PubMed ID: 10598045
[TBL] [Abstract][Full Text] [Related]
7. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
[TBL] [Abstract][Full Text] [Related]
8. Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens.
Brodie A; Jelovac D; Long BJ
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):455S-9S. PubMed ID: 12538500
[TBL] [Abstract][Full Text] [Related]
9. Aromatase inhibitors and breast cancer.
Macedo LF; Sabnis G; Brodie A
Ann N Y Acad Sci; 2009 Feb; 1155():162-73. PubMed ID: 19250202
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG
Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540
[TBL] [Abstract][Full Text] [Related]
11. Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model.
Macedo LF; Sabnis GJ; Goloubeva OG; Brodie A
Cancer Res; 2008 May; 68(9):3516-22. PubMed ID: 18451180
[TBL] [Abstract][Full Text] [Related]
12. The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens.
Brodie AH; Jelovac D; Long B
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):283-8. PubMed ID: 14623522
[TBL] [Abstract][Full Text] [Related]
13. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
Brodie A; Lu Q; Liu Y; Long B; Wang JP; Yue W
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):36-40. PubMed ID: 9556790
[TBL] [Abstract][Full Text] [Related]
14. Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention.
Sabnis G; Brodie A
Clin Breast Cancer; 2010 Feb; 10(1):E6-E15. PubMed ID: 20133251
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
Sabnis G; Goloubeva O; Jelovac D; Schayowitz A; Brodie A
Clin Cancer Res; 2007 May; 13(9):2751-7. PubMed ID: 17473209
[TBL] [Abstract][Full Text] [Related]
16. Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.
Nukatsuka M; Saito H; Nakagawa F; Abe M; Uchida J; Shibata J; Matsuo K; Noguchi S; Kiniwa M
Breast Cancer Res Treat; 2011 Jul; 128(2):381-90. PubMed ID: 20809360
[TBL] [Abstract][Full Text] [Related]
17. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.
Jelovac D; Sabnis G; Long BJ; Macedo L; Goloubeva OG; Brodie AM
Cancer Res; 2005 Jun; 65(12):5380-9. PubMed ID: 15958587
[TBL] [Abstract][Full Text] [Related]
18. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
Belosay A; Brodie AM; Njar VC
Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
[TBL] [Abstract][Full Text] [Related]
19. Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer.
Núñez NP; Jelovac D; Macedo L; Berrigan D; Perkins SN; Hursting SD; Barrett JC; Brodie A
Clin Cancer Res; 2004 Aug; 10(16):5375-80. PubMed ID: 15328175
[TBL] [Abstract][Full Text] [Related]
20. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Kijima I; Itoh T; Chen S
J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
